Skip to content

A clinical study on the effectiveness of Yunnan Baiyao Capsules combined with internal fixation in promoting healing for patients with hip fracture

A clinical study on the effectiveness of Yunnan Baiyao Capsules combined with internal fixation in promoting healing for patients with hip fracture

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098150
Enrollment
Unknown
Registered
2025-03-04
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hip fracture

Interventions

Interventional group:On the basis of internal fixation for hip fracture, the patient took Yunnan Baiyao capsule orally (0.25g, 2 capsules/times, 4 times a day) starting from the first day after surger
Control group:Internal fixation of hip fracture was performed after hip fracture

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. 60 years old <= age <= 75 years old; 2. Patients undergoing internal fixation surgery for hip fractures are diagnosed using the diagnostic criteria for hip fractures in the International Classification of Diseases, Tenth Revision (ICD-10), including femoral neck fractures and intertrochanteric fractures; 3. Patients who had not participated in other clinical trials within 90 days prior to inclusion; 4. Complete case data; 5. Voluntarily follow all research procedures of the test plan; 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with multiple fractures, pathological fractures and old fractures; 2. Suffering from bone metabolic disorders; 3. Long-term use of alcohol or hormone drugs; 4. Patients with malignant tumors, liver and kidney insufficiency or other serious diseases of multiple organs; 5. Patients with mental illness or cognitive impairment; 6. Combined with coagulation dysfunction; 7. Patients with abnormal thyroid function; 8. Severely malnourished persons; 9. Pregnant or lactating women; 10. Failure to comply with protocol or test requirements; 11. Participants who have participated in other clinical trials within the last 3 months; 12. Other circumstances that the researcher judges are not suitable for inclusion; 13. Patients who are known to be allergic to any basic therapeutic drug, experimental drug or its excipients.

Design outcomes

Primary

MeasureTime frame
Degree of callus healing under X-ray;harris hip score;

Secondary

MeasureTime frame
pain score;Blood D-dimer, fibrinogen (FIB) content;

Countries

China

Contacts

Public ContactGuanglin Wang

Trauma Medical Center, Department of Orthopedics Surgery, West China Hospital, Sichuan University

wglfrank@wchscu.cn+86 189 8060 1391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026